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Abstract  
Background: Regional sampling may identify sites of production or removal of novel 
biomarkers in the circulation; their relationship to haemodynamic measurements may 
clarify their association with the pathophysiology of heart failure.  
Methods: Samples were obtained from up to eight circulatory sites from 22 patients 
with left ventricular dysfunction undergoing elective cardiac catheterisation. The 
plasma concentrations (PC) of six biomarkers [mid-regional pro-atrial natriuretic 
peptide (MR-proANP), C-terminal pro-endothelin-1 (CT-proET-1), mid-regional pro-
adreno-medullin (MR-proADM), pro-calcitonin (PCT), copeptin and galectin-3 (Gal-
3)] were measured.  
Results: Plasma concentrations of MR-proANP were highest in the pulmonary artery 
(PA) and left ventricle, suggesting myocardial production. Lower concentrations of 
copeptin, CT-proET-1, MR-proADM and PCT were found in the supra-renal inferior 
vena cava (SRIVC) sample suggesting renal extraction. Plasma concentrations of 
Galectin-3 varied little by sampling site. Plasma concentrations of MR-proANP 
(r=0.69, p=0.002), MR-proADM (r=0.51, p=0.03), CT-proET-1 (r=0.60, p=0.009) and 
Copeptin (r=0.47, p<0.05) measured from PA samples correlated with PA systolic 
pressure. There was no relation between any measured marker and cardiac index. 
Conclusions: Regional sampling shows variation in the plasma concentration of 
various novel peptides that provides clues to sites of net production and removal. 
Plasma concentrations of several biomarkers were positively correlated with 
pulmonary artery pressure.  
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Introduction 
Cardiac biomarkers, such as natriuretic peptides, have an established role in the 
diagnosis and risk stratification of heart failure (HF) (1-5). Other biomarkers may 
reflect the diverse pathological processes, in the cardiovascular and other systems, 
which contribute to the development and progression of HF and are potential targets 
for novel treatments. Plasma concentrations of biomarkers reflect the net balance 
between production and clearance but cannot distinguish between these two. Little is 
known about sites of production or disposal of many biomarkers or their relationships 
with haemodynamics, which could help explain their associations with adverse 
outcome (6-10).  
 
We sought to evaluate regional differences of six novel biomarkers sampled across 
multiple sites in the arterial and venous circulation to explore likely sites of 
production and disposal. We also studied their association with haemodynamic 
measures of left and right heart function. The biomarkers were chosen to reflect 
different pathways potentially involved in heart failure: mid-regional pro-atrial 
natriuretic peptide (MR-proANP), a stable fragment of the ANP prohormone which 
reflects atrial pressure or transmural stress (11-12);  mid-regional pro-adreno-
medullin (MR-proADM), a vasodilator peptide that may also offer cytoprotection 
(13-15); C-terminal pro-endothelin-1 (CT-proET-1), which mirrors the production of 
endothelin, a potent vasoconstrictor reflecting endothelial dysfunction (16-17);C-
terminal pro-arginine vasopressin (CT-proAVP or copeptin), a measure of AVP 
production (18); ultrasensitive procalcitonin (hsPCT), a marker of infection (19-22); 
and galectin-3, a measure of tissue injury and fibrosis (23-24). All of these markers 
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are elevated in heart failure and, in some way, reflect the severity of disease and 
prognosis (6-9). 
 
Methods 
Study Population  
Twenty-two patients with left ventricular dysfunction (either a reduced left 
ventricular ejection fraction [LVEF <50%] or an increased left atrial diameter [LAD 
>4.0cm] on two-dimensional echocardiography) or a raised left ventricular end-
diastolic pressure [LVEDP >16mmHg] invasively measured) undergoing elective left 
and right heart catheterisation were enrolled (seven patients had significant valvular 
disease, nine had ischemic heart disease (IHD), one had both severe mitral 
regurgitation and IHD, two had an atrial septal defect and one had complete heart 
block with superior vena cava obstruction). The mean age was 65 (+12) years 
(ranging from 30 to 83), thirteen (59%) were men, seven (32%) had atrial fibrillation, 
one had chronic lung disease, 19 had reduced functional capacity due to 
breathlessness, five had a left ventricular ejection fraction <40% and 62% were 
treated with loop diuretics (table 1). 
 
The investigation conformed to the principles outlined in the Declaration of 
Helsinki and all subjects gave their written informed consent.  
 
Cardiac Catheterization 
 
regional circulatory bio-marker distribution 
Page 6 of 18 
 
Cardiac catheterisation was performed in the afternoon with patients in a fasting state. 
Catheters were inserted via the femoral artery and vein to measure:  pulmonary artery 
(PA), pulmonary capillary wedge (PCWP), right atrial, systemic arterial and LV end-
diastolic pressures. Cardiac output was measured by the direct Fick method. Venous 
samples were collected from up to five circulatory sites: the low inferior vena cava 
(LIVC), supra -renal inferior vena cava (SRIVC), high inferior vena cava (at the level 
of the hepatic vein; HIVC), superior vena cava (SVC) and pulmonary artery (PA). 
Arterial samples were collected from the left ventricle (LV) and aortic root. In five 
cases, samples were also obtained from the coronary sinus. After samples were 
collected, all patients underwent coronary arteriography and left ventriculography. 
 
Plasma concentrations were compared using aortic samples as reference. In addition, 
an estimate of net cardiac production or removal was made by comparing biomarker 
concentrations in the PA with calculated mixed venous blood using the formula 
(mixed venous concentration = ((3 x SVC) + HIVC)/4. Further comparisons were 
made to explore net renal (LIVC to SRIVC), hepatic (SRIVC to HIVC) and lung (PA 
to LV) production or removal.  
 
Samples were collected into ethylene-diamine-tetra-acetic acid (EDTA) vacutainers. 
The vacutainers were centrifuged immediately after collection at 3000 rpm for 15 
minutes at 4C.  The plasma was removed from each and stored in a cryotube at -
80C prior to batch analysis. The plasma concentrations (PC) of MR-proANP, CT-
proET-1, MR-proADM, hsPCT and copeptin were measured using a kryptor analyser 
(B.R.A.H.M.S. AG, Henningsdorf, Germany), a fully automated system based on 
time-resolved amplified cryptate emissions (TRACE) technology. Galectin-3 was 
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measured using a manual enzyme-linked immuno-sorbent assay (BG Medicine, 
Waltham MA, USA).  
 
All samples were measured in duplicate and the average value of the two 
measurements was used. 
 
The lower limits of detection for these assays were 2.1 pmol/L for MR-proANP, 0.05 
nmol/L for MR-proADM, 3.0 pmol/L for CT-proET-1, 4.8 pmol/L for copeptin and 7 
ng/L for ultrasensitive PCT. The functional assay sensitivities, defined as the 
concentration at which the inter-assay coefficient of variation (CoV) was 20%, were 
10 pmol/L for MR-proANP, 0.25 nmol/L for MR-proADM, 10 pmol/L for CT-proET-
1, 12 pmol/L for copeptin and 30 ng/L for ultrasensitive PCT. 
 
 
Statistical methods 
Regional differences were expressed as the mean and percentage change. The plasma 
concentrations of biomarkers were log transformed if they were not normally 
distributed. Where samples were missing, comparisons were made only where there 
was a sample in both regions.  The differences in the mean assay values between each 
of the circulatory sites were compared using the paired t-test for related samples. 
Formal adjustments for multiple comparisons were not made as the study was 
exploratory to generate rather than prove a hypothesis. The correlations between 
plasma concentrations of different biomarkers and haemodynamic measurements 
were examined using Pearson correlation coefficient and scatter plots for samples 
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obtained in the aorta and in the pulmonary artery. Due to the exploratory nature of this 
study, statistical significance was set at a p-value <0.1. 
 
Results 
Patient characteristics 
Demographic and echocardiographic characteristics, medications and blood results for 
the study population are reported in Table 1.    
 
Differences in regional circulatory distribution and relationship with 
haemodynamic measurements (Figures 1 to 6 and Table 2).  
 
MR-proANP. Plasma concentrations of MR-proANP fell between aorta and SRIVC, 
suggesting renal extraction, and increased again in the pulmonary artery suggesting a 
contribution from the coronary sinus and/or right heart (figure 1). The drop in 
concentration between the aorta and the SRIVC was close to 10% (p=0.0004) and 
there was a significant relationship between eGFR and this difference, again 
suggesting renal clearance (Figure 7). MR-proANP measured from PA samples 
correlated with age [R=0.59; P=0.010] and systolic PA [R=0.69; P=0.002] and mean 
PA [R=0.78; P<0.001] and end diastolic left ventricular filling [R=0.55; P=0.02] 
pressures. 
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MR-proADM. Plasma concentrations of MR-proADM increased between the aorta 
and the low IVC, consistent with production by the capillary endothelium, fell in the 
SRIVC, suggesting extraction in the renal circulation, and then rose again in HIVC, 
suggesting a contribution from the splanchnic circulation (Figure 2). Plasma 
concentrations measured in the PA correlated with age [R=0.66; P=0.003] and 
systolic PA [R=0.51; P=0.03] and mean PA [R=0.56; P=0.02] pressures.  
 
CT-proET-1. Plasma concentrations of CT-proET-1 decreased from the LV to the 
aorta, where there was a statistically significant step down; the explanation for this is 
not clear (Figure 3). CT-proET-1 concentrations measured in the PA correlated with 
age [R=0.71; P=0.001] and systolic PA [R=0.60; P=0.009], mean PA [R=0.54; 
P=0.02] and RA [R=0.58; P=0.01] pressures and weakly with cardiac index. 
 
Copeptin. Plasma concentrations of copeptin dropped between the aorta and SRIVC 
and then increased in the HIVC (Figure 4). Copeptin measured in the PA correlated 
with age [R=0.47; P=0.051] and systolic PA pressure [R=0.47; P=0.048]. 
 
Ultrasensitive pro-calcitonin. Plasma concentrations of pro-calcitonin fell between 
aorta and SRIVC and rose again in the HIVC (Figure 5). No correlations were found 
between pro-calcitonin measured in the PA and haemodynamic measurements.  
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Galectin-3. Plasma concentrations of Galectin-3 plasma were similar in the right and 
left circulation, although its plasma concentrations decreased between LIVC and 
SRIVC, suggesting renal clearance (Figure 6).  Galectin-3 measured in the PA 
correlated with eGFR [R=-0.54; P=0.02] and weakly with mean PA pressure, but 
there were no other correlations between galectin-3 concentration and haemodynamic 
measurements. 
Samples were obtained from the coronary sinus in only five patients. These suggested 
a net contribution for MR-proANP (8.6%), CT-proET-1 (6.5%) and hsPCT (5.8%) but 
no net contribution from other markers (0% - 1.0%). 
 
Discussion 
This study provides insights into the sites of production and clearance of novel cardiac 
biomarkers. We observed a general pattern for the majority of the biomarkers: their 
plasma concentrations were often lower in the SRIVC compared to the aorta, 
suggesting renal clearance, were higher when PA pressures were raised and were 
unrelated to cardiac index, systemic blood pressure or systemic vascular resistance. 
 
MR-proANP is a fragment of the A-type natriuretic peptide pro-hormone produced by 
cardiomyocytes in response to pressure or fluid overload. ANP enhances natriuresis 
and may be considered part of the body’s defence against congestion. The highest 
plasma concentrations were found in the aorta and pulmonary artery, consistent with 
cardiac production. Of the biomarkers we measured, only MR-proANP was related to 
LVEDP (11); lower concentrations in the SRIVC suggest renal extraction (12).  
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Adrenomedullin is a vasodilator peptide that was originally discovered in a 
phaeochromocytoma. (13) It is produced by the endothelium at a rate similar to that of 
endothelin-1 in cultured vascular endothelial cells (14). The drop between the aorta 
and SRIVC suggests renal extraction.  The increase at the HIVC level suggests that 
the adrenal glands or splanchnic circulation might contribute to its production. A 
similar pattern was shown for CT-proET-1, although changes were less marked. No 
net change across the pulmonary circulation was observed for either marker (15, 16) 
but their association with pulmonary artery pressures suggests that the pulmonary 
circulation might have a role in their turnover (17).   
 
Copeptin is an inactive fragment of a pre-prohormone synthesised in the 
hypothalamus and co-secreted with vasopressin from the posterior pituitary. The 
highest plasma concentrations were in the superior vena cava consistent with its 
known site of production.  Although it is unknown how copeptin is removed from the 
circulation, concentrations were lower in the SRIVC, suggesting renal extraction. 
Copeptin degradation fragments have been detected in urine. (18). 
 
Procalcitonin (PCT) is a biomarker related to the presence and severity of infection 
(19) but plasma concentrations may be modestly elevated in HF even when evidence 
of infection is absent (20). Raised plasma PCT concentrations are associated with a 
worse prognosis (21). Patients with heart failure may have altered gut permeability 
due to bowel congestion and this may lead to absorption of bacterial endotoxins 
stimulating PCT release (22). In our population, PCT was not associated with the 
haemodynamic severity of disease. Again, we found evidence of renal extraction of 
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PCT. The rise in PCT in the HIVC suggests that liver and other abdominal organs 
might be extra-thyroidal sites of PCT production.   
 
Galectin-3 promotes macrophage migration, fibroblast proliferation and collagen 
synthesis, all of which are important steps in the genesis of myocardial fibrosis (23). 
In animal models, high galectin-3 promotes cardiac fibrosis and ventricular 
dysfunction (24). We found no substantial variability in galectin-3 other than a drop 
between LIVC and SRIVC, again suggesting renal extraction (25).  
 
Current evidence suggests that measurements of right rather than left heart function 
may be the more important determinant of prognosis in patients with HF; an elevated 
pulmonary pressure may play a key role in the development of RV dysfunction (26-
28). Plasma concentrations of most of the biomarkers we measured correlated with 
PA pressure which might explain some of the association between biomarker 
concentrations and outcome in patients with HF (6-9). 
 
Limitations 
The present study can only be considered exploratory due to its size. Verification by 
others would be welcome. The halve-lives of these biomarkers in the circulation are 
unknown but many are relatively stable fragments with relatively low clearance rates. 
Net changes across a circulatory bed may be difficult to observe when turnover is 
low. We investigated only net changes and not turnover that would have required 
isotopic labelling of markers. It is possible that production and extraction of a 
biomarker may be balanced across a circulatory bed; under conditions other than 
those in our study, this balance may be disturbed. We did not take a peripheral blood 
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sample from an antecubital vein and so we cannot be sure of the relationship between 
our findings and plasma concentrations in samples that would be obtained in routine 
practice. We did not specifically cannulate and obtain samples from the renal or 
splanchnic veins that might have demonstrated more pronounced changes. This 
population was heterogeneous with only five patients having substantial LV systolic 
dysfunction. Moreover, patients were recruited from a cohort of patients undergoing 
elective left and right heart catheterization, thus these results do not apply to patients 
who are acutely ill. Patients were studied under artificial conditions (supine position; 
absent muscle activity). There were several minutes between acquisition of the first 
and last sample, which might have affected our results.  
 
Conclusions 
This study shows that regional circulatory differences exist in plasma concentrations 
of many biomarkers, that extraction across the renal circulation is a common feature 
for many and that their plasma concentrations rise when PA pressures increase; 
presumably reflecting congestion. This may explain why elevated plasma 
concentrations are associated with adverse prognosis.  
 
Disclosures: JGFC has received research funding from Thermo Fisher 
Scientific (formerly B.R.A.H.M.S) and RN was employed using this research 
funding.  
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Legend to figures 
Figure 1 to 6: Differences in the mean plasma concentration for each of the 
circulatory sites compared with that from aortic samples (reference site). Suprarenal 
inferior vena cava (SRIVC), low inferior vena cava (LIVC), high inferior vena cava 
(HIVC), superior vena cava (SVC) and coronary sinus when available (CS). To 
further explore the net organ contribution, comparison between LIVC and SRIVC 
(renal), SRIVC and HIVC (splanchnic), pulmonary artery (PA) and left ventricle (LV; 
lungs), Mixed venous ((3xSVC))+ HIVC/4) and PA (cardiac), and finally LV and 
Aorta were made. Where samples were missing comparisons were made only where 
there was a sample in both regions.   
Figure 7: relationship between estimated Glomerular Filtration Rate (eGFR) and the 
changes in MR-proANP (%) between aorta and suprarenal inferior vena cava.  
Patient Characteristics  
 
Demographic  
Age – years 65 (12) 
Male – no. (%) 13 (59) 
IHD - no. (%) 10 (45) 
Diabetes - no. (%) 2 (9) 
Hypertension - no. (%) 4 (18) 
COPD - no. (%) 1 (4) 
Atrial fibrillation- no. (%) 7 (32) 
NYHA class – no. (%) 
I 3 (14) 
II 18 (82) 
III 1 (4) 
BMI – kg/m2 25 (7) 
Heart rate – bpm 75 (15) 
Blood results  
Haemoglobin – g/dl 13.6 (1.8) 
Creatinine – umol/l 89 (19) 
Urea – mmol/l 6.1 (4.1 – 7.5) 
eGFR - ml/min/1.73m2 77 (18) 
Echocardiographic Data  
LVEF - % 55 (41-60) 
LVEF <40% – no. (%) 5 (23) 
LAD – mm 45 (10) 
Moderate or Severe mitral regurgitation 5 (23) 
Moderate or Severe tricuspid regurgitation 8 (36) 
Medications – no. (%)  
Beta-blocker 15 (67) 
ACE inhibitor or ARB 11 (50) 
Loop Diuretics 14 (63) 
Aldosterone Antagonists   7 (32) 
 
 
Table 1: Patient Characteristics. The data shown is mean and standard deviation if the 
variable is normally distributed or median and inter-quartile range if not. List of abbreviations 
used: IHD - Ischaemic Heart Disease; COPD - Chronic Obstructive Pulmonary Disease; BMI 
- Body Mass Index; eGFR - estimated Glomerular Filtration Rate; LVEDD - Left Ventricle 
End-Diastolic Diameter; LVEF – Left Ventricular Ejection Fraction; LA - Left Atrial 
Diameter.  
 
  
 Median 
Values in 
PA (IQR) 
Age 
years 
BMI  
kg/m2 
eGFR 
ml/min/
1.73m2  
RAP- 
mmHg 
SPAP- 
mmHg 
MPAP 
mmHg 
PVR 
dyn·s/cm5 
PCWP 
mmHg 
LVEDP 
mmHg 
CI l/min/m2 SAP 
mmHg 
SVR  
dyn·s/cm5 
 
Median (IQR) 
 
66 
(57-75) 
25 
(21-29) 
77 
(67-88) 
8 
(4-12) 
41 
(29-51) 
28 
(19-34) 
233 
(32-310) 
19 
(10-25) 
15 
(9-22) 
1.81 
(1.65-2.25) 
125 
(106-162) 
1623 
(1433-2344) 
  
Pearson’s Correlation, r (p-value) 
MR-proANP* 
pmol/l 
232 
(149-325) 
0.590 
(0.01) 
-0.186 
(0.46) 
-0.254 
(0.31) 
0.244 
 (0.33) 
0.690 
(0.002) 
0.780 
(<0.001) 
0.262 
(0.34) 
0.337 
(0.22) 
0.545 
(0.02) 
-0.208 
(0.41) 
0.045 
(0.86) 
0.184 
(0.46) 
MR-proADM 
nmol/l 
0.76 
(0.60-1.06) 
0.658 
(0.003) 
-0.007 
(0.98) 
-0.376 
(0.12) 
0.460 
(0.05) 
0.513 
(0.03) 
0.561 
(0.01) 
0.239 
(0.39) 
0.216 
(0.44) 
0.314 
(0.22) 
-0.248 
(0.32) 
-0.213 
(0.37) 
-0.078 
(0.76) 
CT-ProET1 
pmol/l 
93  
(68-102) 
0.712 
(0.001) 
-0.334 
(0.17) 
-0.368 
(0.13) 
0.582 
(0.01) 
0.595 
(0.009) 
0.544 
(0.02) 
0.199 
(0.47) 
0.327 
(0.24) 
0.111 
(0.67) 
-0.439 
(0.07) 
-0.227 
(0.36) 
0.014 
(0.96) 
Copeptin* 
pmol/l 
10.3 
(7.8-16.5) 
0.466 
(0.05) 
-0.101 
(0.69) 
-0.415 
(0.08) 
0.368 
(0.13) 
0.472 
(0.05) 
0.365 
(0.14) 
0.455 
(0.09) 
-0.120 
(0.67) 
0.100 
(0.70) 
-0.273 
(0.27) 
-0.271 
(0.28) 
-0.117 
(0.64) 
Procalcitonin* 
ng/L 
29.8 
(18.0-40.3) 
0.363 
(0.14) 
-0.248 
(0.32) 
-0.022 
(0.93) 
0.405 
(0.09) 
0.371 
(0.13) 
0.158 
(0.53) 
0.240 
(0.39) 
-0.133 
(0.64) 
-0.211 
(0.42) 
-0.173 
(0.49) 
-0.264 
(0.29) 
0.074 
(0.77) 
Galectin-3 
ng/ml 
17.8 
(12.3-21.4) 
0.398 
(0.10) 
0.043 
(0.86) 
-0.541 
(0.02) 
0.127 
(0.62) 
0.384 
(0.11) 
0.439 
(0.07) 
-0.074 
(0.79) 
0.205 
(0.46) 
-0.038 
(0.88) 
0.046 
(0.86) 
-0.034 
(0.89) 
-0.187 
(0.46) 
